Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Details Narrative)

v3.21.2
Stockholders Equity (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 16, 2021
Apr. 19, 2019
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2017
Conversion price     $ 3.40 $ 3.40      
Common stock, par value     $ 0.001 $ 0.001   $ 0.001  
Common stock shares granted for consultants 2,502,518            
Fair value of stock options granted for consultants $ 9,679,000            
Proceeds from exercise of warrants       $ 16,433,000 $ 0    
Common shares issued upon exercise of warrants       3,076,017      
Common stock shares vested 1,829,620            
Common stock shares vest over two years 672,898            
Unvested shares of common stock       509,772      
Fair value of stock options granted       $ 1,789,000      
Issuance of Common Stock in public offering 4,945,000            
Issuance of Common Stock in public offering, amount $ 24,679,000            
Purchase of warrants 5,192,250            
Convertible note payable $ 38,799,000   $ 38,799,000 38,799,000      
Principal amount     33,272,000 33,272,000      
Accrued interest     $ 0 0   $ 4,838,000  
Debt conversion debt instrument , shares 11,413,322            
Stock compensation expense       $ 7,890,000      
Price per share $ 5.50            
Exercise price of warrant $ 5.50            
Shares of common stock issue     10,408,827 10,408,827      
Notes payable related party     $ 35,383,000 $ 35,383,000      
Unissued shares of common stock     1,004,495 1,004,495      
Common stock shares issued upon submission of transfer agent       74,094      
Common stock issuable amount       $ 3,416,000      
Converted conversion of common stock 11,413,322            
Common stock, Shares Issued During Period       1,992,746      
Intrinsic value of warrants     $ 3,180,000 $ 3,180,000      
Aggregate shares of common stock 5,192,250            
Shares of common stock upon exercise of warrants       3,073,818      
Shares of common stock upon exercise of warrants, amount       $ 16,433,000      
Issuance of Common Stock for research and development agreement, amount     $ 327,000 $ 9,103,000 $ 180,000    
Preferred stock, par value     $ 0.01 $ 0.01   $ 0.01  
Common Stock Issuable              
Convertible note payable     $ 3,416,000 $ 3,416,000      
Accrued interest $ 5,527,000            
Consultants [Member]              
Stock compensation expense       9,103,000      
Fully vested shares, amount       $ 1,213,000      
Series C Preferred Stock [Member]              
Common stock, par value     $ 0.01 $ 0.01      
Preferred stock, issued     96,230 96,230     96,230
Description of conversion ratio       The conversion ratio is based on the average closing bid price of the common stock for the fifteen consecutive trading days ending on the date immediately preceding the date notice of conversion is given, but cannot be less than $3.40 or more than $4.9113 for each share of Series C Preferred Stock. The conversion ratio may be adjusted under certain circumstances such as stock splits or stock dividends. The Company has the right to automatically convert the Series C Preferred Stock into common stock if the Company lists its shares of common stock on the Nasdaq National Market and the average closing bid price of the Company’s common stock on the Nasdaq National Market for 15 consecutive trading days exceeds $3,000.00. Each share of Series C Preferred Stock is entitled to the number of votes equal to 0.26 divided by the average closing bid price      
Common Stock [Member]              
Issuance of Common Stock for research and development agreement       189,753      
Issuance of Common Stock for research and development agreement, amount       $ 1,355,000      
Series J Preferred Stock [Member]              
Conversion price $ 3.40 $ 3.40          
Preferred stock, issued     692,220 692,220      
Preferred stock shares designated 2,000,000            
Preferred stock, par value   $ 0.01          
shares issued exchange of cancellation of indebtness   840,000   1,513,548      
Beneficial conversion percantage   9.99%          
Presferred stock shares outstanding     692,220 692,220      
Public offering shares 2,353,548            
Series K Preferred Stock [Member]              
Preferred stock shares designated 115,000            
Preferred stock, par value $ 0.01